18-Mar-2020: The global ovarian cancer
diagnostics market size
is expected to reach USD 2 billion by 2026, according to a new report by Grand
View Research, Inc., exhibiting a CAGR of 6.2%. The growth of the market can be
attributed to an increase in the prevalence of ovarian cancer and emergence of
novel diagnostic products. As of 2018, ovarian cancer had the highest mortality
rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the
U.S. in 2018. No specific symptoms render early diagnosis of the disease
increasingly difficult. The exact causative factors remain unknown, creating a
key unmet need for further research to obtain clarity on the underlying
molecular mechanisms.
Women aged 60 years
& above have a higher predisposition to it. As it is often diagnosed in
advanced stages, treatment options are limited. Moreover, on the basis of race,
incidence rates were higher among Caucasian women than African-American women.
The International Federation of Gynecology and Obstetrics (FIGO) system is used
for staging ovarian cancer. Staging process helps identify ovarian tumors,
calculate their size, and detect invasion & metastasis.
Early detection and
diagnosis significantly improve patient survival rates. For instance, in case
of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate
of nearly 90%, whereas patients with stage 4-the most advanced phase-have a
mere 15% survival rate. Technological advancements in PET and MRI as well as in
diagnosis of BRCA mutations have positively impacted market growth.
The diagnostic
landscape is gradually shifting toward genetic testing and counseling. As the
disease bears a high risk of inheritance of gene mutation, guidelines
pertaining to ovarian cancer diagnostics recommend all patients to undergo
genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test;
however, advancements in medical science have now made it possible to test more
than 20 genes in each patient.
In
depth research report on Ovarian Cancer Diagnostics Market
Further key findings from the report suggest:
·
Incidence of ovarian cancer worldwide has been declining over
the past decades
·
Although ultrasound imaging is the fist-line of diagnosis,
the technique cannot be used for staging the disease
·
Computerized Tomography (CT) imaging is preferred for staging
the disease
·
CA125 remained the mainstay in blood test biomarkers in 2018
·
HER2 and BRCA1/2 tests are expected to witness a rapid growth
during the forecast period owing to the rising awareness of early diagnosis and
genetic tests
·
The ovarian cancer diagnostics market in Asia Pacific is
expected to grow at a high rate during the forecast period.
Grand View Research
has segmented the global ovarian cancer diagnostics market on the basis of
cancer type, diagnosis type, end use, and region:
Ovarian Cancer Diagnostics Cancer Type Outlook (Revenue, USD
Million, 2015 - 2026)
·
Epithelial Tumor
·
Germ Cell Tumor
·
Stromal Cell Tumor
·
Others
Ovarian Cancer Diagnostics Diagnosis Type Outlook (Revenue,
USD Million, 2015 - 2026)
·
Imaging
·
Ultrasound
·
CT Scan
·
MRI Scan
·
PET Scan
·
Others
·
Blood Test
·
CA125
·
HER2
·
BRCA
·
CEA
·
ER & PR
·
KRAS Mutation
·
Others
·
Biopsy
·
Others
Ovarian Cancer Diagnostics End-use Outlook (Revenue, USD
Million, 2015 - 2026)
·
Hospital Laboratories
·
Cancer Diagnostic Centers
·
Research Institutes
·
Others
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is the
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment